# Coultreon Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coultreon-biopharma

- Industry: Biotechnology
- Headquarters: Leuven, Belgium
- Website: www.coultreon.com
- Total disclosed funding: $63M
- Latest round: Series A (Apr 28, 2026)
- Investors on record: 10

## About

Coultreon Biopharma BV, located in Leuven, Belgium, specializes in research and development of advanced therapeutics aimed at treating chronic inflammatory diseases and autoimmune conditions. Coultreon Biopharma was co-founded by Pierre Raboisson (Chief Executive Officer and Chief Scientific Officer), Marie De Vulder, Guy Peeters, John-Paul Gallivan, Fabrice Kolb, Pieter Peeters, François Gonzalvez, Sandrine Vendeville, and Joost Kolkman.Founded in 2025, Coultreon Biopharma BV focuses on innovative therapies for chronic inflammatory diseases. The company has not undergone significant pivots in its strategy. It has completed 1 deal, In April 2026, Coultreon Biopharma BV raised EUR 53.52 million in series A funding co-led by  Sofinnova Investments, Forbion, and Novo Holdings, with participation from other investors Galapagos Capital, Regeneron Ventures, BAM Elevate, Luma Group, Samsara BioCapital, Longwood Fund, and Finchley Healthcare Ventures.Coultreon Biopharma primarily focuses on developing innovative therapeutics for patients suffering from chronic inflammatory diseases, specifically targeting autoimmune conditions. Their core product, COL-5671, is a highly selective SIK3 inhibitor designed to modulate inflammatory pathways while providing a well-tolerated and convenient oral treatment option. This therapeutic aims to provide a multifaceted approach to managing diseases such as ulcerative colitis by simultaneously suppressing pathogenic cytokines like TNFa and IL-12 while promoting anti-inflammatory mediators like IL-10. The company serves a wide range of patients worldwide, particularly in Europe and North America, where there is a pressing demand for more effective oral medications that address significant unmet medical needs. Coultreon Biopharma's commitment to advancing therapeutic solutions is underscored by their proprietary AI-augmented drug design platform, which enhances their ability to optimize lead assets for clinical success.Coultreon Biopharma's revenue structure is primarily derived from the commercialization of its flagship product, COL-5671, along with potential future offerings targeting a range of chronic inflammatory diseases. Revenue transactions are structured around partnerships with healthcare providers, clinical trial agreements, and potential licensing arrangements with pharmaceutical companies. As the company progresses through clinical trials and approaches market readiness, it may consider subscription models or direct sales to hospitals and specialty pharmacies. Pricing plans for COL-5671 would be aligned with industry standards for advanced therapeutics, reflecting its unique mechanism of action and potential for improved patient outcomes. Through these revenue channels, Coultreon aims to establish a solid financial foundation while continuing to drive innovation in the biopharmaceutical sector. The funding will be utilized to advance its lead program COL-5671 into Phase 2 clinical trials for psoriasis and ulcerative colitis, as well as to support further clinical development of its immunology pipeline. Plans to expand into new markets, particularly in North America and Europe, are anticipated by 2027.

## Funding rounds

- Series A, Apr 28, 2026, $63M — Sofinnova Investments, Novo Holdings, Forbion, Longwood Fund, Samsara BioCapital, Galapagos Capital, BAM Elevate, Luma Group, Regeneron Ventures, Finchley Healthcare Ventures

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A
- Novo Holdings — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A
- Galapagos Capital — Series A
- BAM Elevate (https://capitalatlas.ai/funds/bam-elevate) — Series A
- Luma Group (https://capitalatlas.ai/funds/luma-group) — Series A
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series A
- Finchley Healthcare Ventures (https://capitalatlas.ai/funds/finchley-healthcare-ventures) — Series A